Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.

Sonne DP, Engstrøm T, Treiman M

Regulatory peptides13 Oct 2007Cited by 220 (Europe PMC)

PMID17976835DOI10.1016/j.regpep.2007.10.001PepBankPUB-17976835

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueEfficacy outcome
In isolated rat hearts after ischemia, exendin‑4 reduced infarct size from 33.2% to 14.5% of the ischemic area.
In plain wordsIn lab tests on rat hearts, exendin‑4 reduced infarct size after interrupted blood flow.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct size
Study
ratn: not reported in source
Isolated heart ischemia-reperfusion preparation
Outcome group
Heart function · Cardiovascular
Studied dose
0.03-3.0 nM · First 15 min of reperfusionAs given in this study (rat).
Source sentences
Summary
Exe-4, but not GLP-1(9-36) amide, showed a strong infarct-limiting action (from 33.2% +/-2.7% to 14.5% +/-2.2% of the ischemic area, p<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Here we tested exendin-4 (Exe-4), a peptide agonist at GLP-1 receptors, and GLP-1(9-36) amide, the primary endogenous metabolite of GLP-1 (both in the concentration range 0.03-3.0 nM), for their protective effects against ischemia-reperfusion injury (IRI) in an isolated rat heart preparation.
Summary · context
When administered, the agents were only present for the first 15 min of a 120 min reperfusion period (postconditioning protocol).
Report a problemFND-1797683501
02LabEx vivo tissueEfficacy outcome
In isolated rat hearts, exendin‑4 increased left ventricular developed pressure during late reperfusion.
In plain wordsIn lab tests on rat hearts, exendin‑4 increased ventricular pressure during restored blood flow.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseLeft ventricular developed pressure
Study
ratn: not reported in source
Isolated heart ischemia-reperfusion preparation
Outcome group
Heart function · Cardiovascular
Studied dose
0.03-3.0 nM · First 15 min of reperfusionAs given in this study (rat).
Source sentences
Summary
In contrast, both Exe-4 and GLP-1(9-36) amide were able to augment left ventricular performance (left ventricular developed pressure and rate-pressure product) during the last 60 min of reperfusion.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we tested exendin-4 (Exe-4), a peptide agonist at GLP-1 receptors, and GLP-1(9-36) amide, the primary endogenous metabolite of GLP-1 (both in the concentration range 0.03-3.0 nM), for their protective effects against ischemia-reperfusion injury (IRI) in an isolated rat heart preparation.
Summary · context
When administered, the agents were only present for the first 15 min of a 120 min reperfusion period (postconditioning protocol).
Report a problemFND-1797683503
03LabEx vivo tissueEfficacy outcome
In isolated rat hearts, exendin‑4 increased rate-pressure product during late reperfusion.
In plain wordsIn lab tests on rat hearts, exendin‑4 increased the product of heart rate and ventricular pressure.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseRate-pressure product
Study
ratn: not reported in source
Isolated heart ischemia-reperfusion preparation
Outcome group
Heart function · Cardiovascular
Studied dose
0.03-3.0 nM · First 15 min of reperfusionAs given in this study (rat).
Source sentences
Summary
In contrast, both Exe-4 and GLP-1(9-36) amide were able to augment left ventricular performance (left ventricular developed pressure and rate-pressure product) during the last 60 min of reperfusion.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we tested exendin-4 (Exe-4), a peptide agonist at GLP-1 receptors, and GLP-1(9-36) amide, the primary endogenous metabolite of GLP-1 (both in the concentration range 0.03-3.0 nM), for their protective effects against ischemia-reperfusion injury (IRI) in an isolated rat heart preparation.
Summary · context
When administered, the agents were only present for the first 15 min of a 120 min reperfusion period (postconditioning protocol).
Report a problemFND-1797683504

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

04LabNot a test of Exenatide (exendin-4) aloneEx vivo tissueMechanism
In isolated rat hearts, exendin(9-39) abolished the infarct-limiting effect of exendin‑4.
In plain wordsIn lab tests on rat hearts, a receptor blocker abolished the infarct-limiting effect of exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseInfarct limitation under receptor antagonism
Study
ratn: not reported in source
Isolated heart ischemia-reperfusion preparation
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
This infarct size-limiting effect of Exe-4 was abolished by exendin(9-39) (Exe(9-39)), a GLP-1 receptor antagonist.
2 context sentences(design, population, supporting numbers)
Summary · context
Here we tested exendin-4 (Exe-4), a peptide agonist at GLP-1 receptors, and GLP-1(9-36) amide, the primary endogenous metabolite of GLP-1 (both in the concentration range 0.03-3.0 nM), for their protective effects against ischemia-reperfusion injury (IRI) in an isolated rat heart preparation.
Summary · context
When administered, the agents were only present for the first 15 min of a 120 min reperfusion period (postconditioning protocol).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1797683502
05LabNot a test of Exenatide (exendin-4) aloneEx vivo tissueMechanism
In isolated rat hearts, exendin(9-39) only partially blocked the ventricular performance effects of exendin‑4.
In plain wordsIn lab tests on rat hearts, a receptor blocker only partly blocked the heart performance effects of exendin‑4.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVentricular performance under receptor antagonism
Study
ratn: not reported in source
Isolated heart ischemia-reperfusion preparation
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
These effects were only partially antagonized by Exe(9-39).
3 context sentences(design, population, supporting numbers)
Summary · context
In contrast, both Exe-4 and GLP-1(9-36) amide were able to augment left ventricular performance (left ventricular developed pressure and rate-pressure product) during the last 60 min of reperfusion.
Summary · context
Here we tested exendin-4 (Exe-4), a peptide agonist at GLP-1 receptors, and GLP-1(9-36) amide, the primary endogenous metabolite of GLP-1 (both in the concentration range 0.03-3.0 nM), for their protective effects against ischemia-reperfusion injury (IRI) in an isolated rat heart preparation.
Summary · context
When administered, the agents were only present for the first 15 min of a 120 min reperfusion period (postconditioning protocol).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-1797683505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT01761318

Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients

Leiden University Medical Centern = 50Nov 2013 to Mar 2016

Diabetes Mellitus Type 2 · Metabolic Syndrome · Cardiovascular Disease · Diastolic Dysfunction · Fatty Liver

Trial page ClinicalTrials.govUpdated 5 May 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.